Hybrid Power Solutions reported a 707% year-over-year revenue increase to $886,333 in Q4 fiscal 2026, driven by higher sales volumes of its clean power systems. The company narrowed its quarterly net loss by 52% compared to the previous quarter, reflecting improved operational efficiency and cost management. With a strong sales pipeline of $19.3 million, including growth in defence and public safety sectors, Hybrid aims to improve margins and convert opportunities into sustainable revenue in fiscal 2027.
Hybrid Power Solutions' fiscal 2026 Q4 results come alongside a mixed Industrials sector on Pluang, where 45 of 93 US stocks rose and 48 fell as of Sep 30, 2026 03:11 WIB. Among these, FuelCell Energy Inc gained 4.09% to USD 16.80 despite 90% of Pluang orders being sells, contrasting with Redwire Corporation's 4.46% drop to USD 10.70 amid mostly buy orders (89%). Intuitive Machines saw a 4.01% decline to USD 14.59 with all Pluang orders buying, and a notably short typical hold time of 3 days.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
